Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience
Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, partic...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Wiley-Blackwell Publishing Ltd.
2019
|
| Online Access: | http://hdl.handle.net/20.500.11937/74146 |
Similar Items
“I'm obviously not dying so it's not something I need to sort out today”: Considering hepatitis C treatment in the era of direct acting antivirals
by: Wright, C., et al.
Published: (2018)
by: Wright, C., et al.
Published: (2018)
Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: A qualitative study
by: Goutzamanis, S., et al.
Published: (2018)
by: Goutzamanis, S., et al.
Published: (2018)
Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
by: Cheung, Michelle C.M., et al.
Published: (2016)
by: Cheung, Michelle C.M., et al.
Published: (2016)
Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial
by: Wade, A., et al.
Published: (2018)
by: Wade, A., et al.
Published: (2018)
Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals
by: Simmons, Ruth, et al.
Published: (2017)
by: Simmons, Ruth, et al.
Published: (2017)
Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
by: Foster, Graham R., et al.
Published: (2016)
by: Foster, Graham R., et al.
Published: (2016)
Reversal of end-stage renal failure using direct-acting antiviral agents for chronic hepatitis C
by: Mitchell, T., et al.
Published: (2016)
by: Mitchell, T., et al.
Published: (2016)
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia
by: Hellard, M., et al.
Published: (2012)
by: Hellard, M., et al.
Published: (2012)
Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral therapy
by: Scott, Robert A., et al.
Published: (2018)
by: Scott, Robert A., et al.
Published: (2018)
Molecular epidemiology and antiviral resistance characterization of Hepatitis C virus circulating in Africa and Brazil
by: Adeboyejo, Kazeem Adeyinka
Published: (2020)
by: Adeboyejo, Kazeem Adeyinka
Published: (2020)
Hepatitis C transmission and treatment as prevention - The role of the injecting network
by: Hellard, M., et al.
Published: (2015)
by: Hellard, M., et al.
Published: (2015)
Barriers to receiving hepatitis c treatment for people who inject drugs myths and evidence
by: Higgs, Peter, et al.
Published: (2011)
by: Higgs, Peter, et al.
Published: (2011)
Preventing hepatitis C virus transmission among young people in the justice system
by: Lenton, E., et al.
Published: (2013)
by: Lenton, E., et al.
Published: (2013)
A response to: Self-reported and actual hepatitis C virus status
by: O'Keefe, D., et al.
Published: (2014)
by: O'Keefe, D., et al.
Published: (2014)
Development of antiviral strategies for treatment of chronic hepatitis B
by: Seow, Heng Fong, et al.
Published: (2002)
by: Seow, Heng Fong, et al.
Published: (2002)
Field engagement further facilitates hepatitis B vaccination completion: Letter in response to: Day et al. (in press)
by: Higgs, Peter, et al.
Published: (2016)
by: Higgs, Peter, et al.
Published: (2016)
Assessment Of Antiviral Usage, Barriers, And Strategies For Scaling Up Hepatitis C Treatment In Malaysia: A Mix Methodology Study
by: Chan, Huan Keat
Published: (2023)
by: Chan, Huan Keat
Published: (2023)
Rapid testing for hepatitis C does not infer current infection
by: Nguyen, V., et al.
Published: (2017)
by: Nguyen, V., et al.
Published: (2017)
Pharmacy-led hepatitis C treatment pathways to help ensure elimination
by: Gunn, J., et al.
Published: (2019)
by: Gunn, J., et al.
Published: (2019)
The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
by: Hellard, M., et al.
Published: (2014)
by: Hellard, M., et al.
Published: (2014)
Hepatitis C treatment - better outcomes through partner support
by: Chapman, Fleur, et al.
Published: (2012)
by: Chapman, Fleur, et al.
Published: (2012)
Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison
by: Lafferty, L., et al.
Published: (2017)
by: Lafferty, L., et al.
Published: (2017)
Hepatitis C treatment in pharmacotherapy services: Increasing treatment uptake needs a critical view
by: Treloar, C., et al.
Published: (2009)
by: Treloar, C., et al.
Published: (2009)
Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?
by: Abo-zeid, Yasmin, et al.
Published: (2018)
by: Abo-zeid, Yasmin, et al.
Published: (2018)
Concordance between self-reported and actual hepatitis C virus infection status in a cohort of people who inject drugs
by: O’Keefe, D., et al.
Published: (2013)
by: O’Keefe, D., et al.
Published: (2013)
Does informing people who inject drugs of their hepatitis C status influence their injecting behavior? Analysis of the Networks II study
by: Aspinall, E., et al.
Published: (2014)
by: Aspinall, E., et al.
Published: (2014)
A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners
by: Yap, L., et al.
Published: (2014)
by: Yap, L., et al.
Published: (2014)
Pharmacies dispensing opioid substitution therapy also play a role in hepatitis C virus elimination
by: Gunn, J., et al.
Published: (2018)
by: Gunn, J., et al.
Published: (2018)
Recombinant human L-ficolin directly neutralizes hepatitis C virus entry
by: Hamed, Mohamed R., et al.
Published: (2014)
by: Hamed, Mohamed R., et al.
Published: (2014)
An antiviral composition.
by: Abu Bakar, Fatimah, et al.
Published: (2011)
by: Abu Bakar, Fatimah, et al.
Published: (2011)
Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin
by: Tawar, Rajiv G., et al.
Published: (2016)
by: Tawar, Rajiv G., et al.
Published: (2016)
Hepatitis B and C in pregnancy
by: Seow, H.F.
Published: (1999)
by: Seow, H.F.
Published: (1999)
Hepatitis C Virus Phylogenetic Clustering Is Associated with the Social-Injecting Network in a Cohort of People Who Inject Drugs
by: Sacks-Davis, R., et al.
Published: (2012)
by: Sacks-Davis, R., et al.
Published: (2012)
Circular antiviral RNA
by: Omar, Abdul Rahman, et al.
Published: (2012)
by: Omar, Abdul Rahman, et al.
Published: (2012)
An antiviral to cure patients
by: Tang, Ashley
Published: (2021)
by: Tang, Ashley
Published: (2021)
Understanding HIV and hepatitis C virus risk among incarcerated young men with histories of injecting drug use
by: Walker, S., et al.
Published: (2019)
by: Walker, S., et al.
Published: (2019)
Effect of ficus deltoidea extracts on hepatic basal and insulin-stimulated glucose uptake
by: Adam, Z., et al.
Published: (2009)
by: Adam, Z., et al.
Published: (2009)
High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study
by: Sacks-Davis, R., et al.
Published: (2013)
by: Sacks-Davis, R., et al.
Published: (2013)
Molecular epidemiology of hepatitis C in Kelantan
by: Amin, Nur Amalin Zahirah Mohd
Published: (2024)
by: Amin, Nur Amalin Zahirah Mohd
Published: (2024)
Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
by: Lattimore, Sam, et al.
Published: (2014)
by: Lattimore, Sam, et al.
Published: (2014)